Roche Holding AG Company Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions.
It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology.
Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
Country | Switzerland |
Founded | 1896 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 103,605 |
CEO | Thomas Schinecker |
Contact Details
Address: Grenzacherstrasse 124 Basel, 4058 Switzerland | |
Phone | 41 61 688 11 11 |
Website | roche.com |
Stock Details
Ticker Symbol | 0QQ6 |
Exchange | London Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | CHF |
ISIN Number | CH0012032113 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Severin Schwan | Chief Executive Officer and Executive Director |
Dr. Alan Hippe | Chief Financial Officer and Information Officer |
Dr. Karl Mahler | Head of Investor Relations |
Dr. Urs Jaisli | Chief Compliance Officer |
Claudia Böckstiegel | General Counsel |
Cristina A. Wilbur | Chief People Officer |
Nicolas Dunant | Head of Group Media Relations |
Ehab Yousef | Head of Middle East Sub-Region 1 |
Boris L. Zaitra | Head of Group M&A |
Lance Duan | Managing Director |